cgp-46381 and Morphine-Dependence

cgp-46381 has been researched along with Morphine-Dependence* in 1 studies

Other Studies

1 other study(ies) available for cgp-46381 and Morphine-Dependence

Article	Year
Attenuation of morphine withdrawal signs by the GABA(B) receptor agonist baclofen. Life sciences, 2001, Dec-14, Volume: 70, Issue:4 The present study examined the effect of the gamma-aminobutyric acidB (GABA(B)) receptor agonist, baclofen on naloxone-induced withdrawal signs in morphine-dependent rats and modification by the antagonist, 3-aminopropyl-cyclohexylmethylphosphinic acid (CGP 46381). Morphine was administered via mini-osmotic pumps for 7 days to induce physical dependence. Baclofen (20 mg kg(-1)) decreased stereotyped head movements, chewing, chatter, ptosis and body weight loss, induced by naloxone (10 mg kg(-1)) in morphine-dependent rats. CGP 46381 (20 mg kg(-1)) reversed the effects exerted by baclofen on stereotyped head movements, ptosis, and weight loss and partially reversed the effect of baclofen on chewing. It can be concluded that baclofen has some potential in the treatment of opioid withdrawal and that GABA(B) receptors may be implicated in such a withdrawal. Topics: Animals; Baclofen; Behavior, Animal; Drug Antagonism; Drug Combinations; GABA Agonists; GABA Antagonists; Male; Morphine Dependence; Naloxone; Phosphinic Acids; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome	2001

Article

Year

Attenuation of morphine withdrawal signs by the GABA(B) receptor agonist baclofen.

Life sciences, 2001, Dec-14, Volume: 70, Issue:4

The present study examined the effect of the gamma-aminobutyric acidB (GABA(B)) receptor agonist, baclofen on naloxone-induced withdrawal signs in morphine-dependent rats and modification by the antagonist, 3-aminopropyl-cyclohexylmethylphosphinic acid (CGP 46381). Morphine was administered via mini-osmotic pumps for 7 days to induce physical dependence. Baclofen (20 mg kg(-1)) decreased stereotyped head movements, chewing, chatter, ptosis and body weight loss, induced by naloxone (10 mg kg(-1)) in morphine-dependent rats. CGP 46381 (20 mg kg(-1)) reversed the effects exerted by baclofen on stereotyped head movements, ptosis, and weight loss and partially reversed the effect of baclofen on chewing. It can be concluded that baclofen has some potential in the treatment of opioid withdrawal and that GABA(B) receptors may be implicated in such a withdrawal.

Topics: Animals; Baclofen; Behavior, Animal; Drug Antagonism; Drug Combinations; GABA Agonists; GABA Antagonists; Male; Morphine Dependence; Naloxone; Phosphinic Acids; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome

2001